The Use of Naltrexone in Dermatology. Current Evidence and Future Directions

Author(s): Mariusz Sikora*, Adriana Rakowska, Małgorzata Olszewska, Lidia Rudnicka.

Journal Name: Current Drug Targets

Volume 20 , Issue 10 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Naltrexone is a competitive opioid receptor antagonist approved as supportive treatment in alcohol dependence and opioid addiction. At a dose of 50-100 mg daily, naltrexone is used off-label in dermatology for the treatment of trichotillomania and different types of pruritus. At a dose as low as 1- 5 mg per day, naltrexone demonstrates immunomodulatory action i.e. modulates Toll-like receptors signaling, decreases release of proinflammatory cytokines (tumor necrosis factor, interleukin-6, interleukin- 12), inhibits T lymphocyte proliferation, down-regulates the expression of chemokine receptors and adhesion molecules. The efficacy of standard and low doses of naltrexone in a variety of dermatological disorders has been reported. These include diseases such as familial benign chronic pemphigus (Hailey-Hailey disease), dermatomyositis, systemic sclerosis, psoriasis and lichen planopilaris. Optimistic preliminary findings, low cost of therapy and good tolerance make naltrexone a promising alternative therapy or adjunct drug in dermatology.

Keywords: Alopecia, low dose naltrexone, opioid growth factor, pruritus, psoriasis, toll-like receptor.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 10
Year: 2019
Page: [1058 - 1067]
Pages: 10
DOI: 10.2174/1389450120666190318121122
Price: $58

Article Metrics

PDF: 15